Prosecution Insights
Last updated: April 19, 2026

Tonix Pharma Limited

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18212500 CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC) BARSKY, JARED 1628 Non-Final OA Jun 21, 2023
18265525 CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA CHONG, YONG SOO 1623 Non-Final OA Jun 06, 2023
17638761 MODIFIED TFF2 POLYPEPTIDES LIEB, JEANETTE M 1654 Non-Final OA Feb 25, 2022
17226058 CYCLOBENZAPRINE TREATMENT FOR SEXUAL DYSFUNCTION CRAIGO, WILLIAM A 1615 Final Rejection Apr 08, 2021
17269106 METHODS OF TREATING ACUTE STRESS DISORDER AND POSTTRAUMATIC STRESS DISORDER BAEK, BONG-SOOK 1611 Non-Final OA Feb 17, 2021

Managing Tonix Pharma Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month